hy-n2959 Search Results


brevilin a  (MedChemExpress)
93
MedChemExpress brevilin a
Effects of <t>brevilin</t> <t>A</t> on cell viability and IL-17A induced IL-6 and IL-8 production in HaCaT cells. (A) HaCaT cells were treated with different doses of brevilin A (0.625, 1.25, 2.5, 5, 10 and 20 µM) or 2% DMSO for 24 h. Cell viability was measured by MTT assay. Results are presented as a percentage of control (untreated) cells. Data are expressed as mean ± SEM (n=3). *P<0.05 vs. control. (B) Concentrations of IL-6 and IL-8 in the supernatant were determined using ELISA kits. HaCaT cells were seeded at a density of 2×10 5 cells/well in a 24-well plate and were co-treated with IL-17A (100 ng/ml) and different concentrations of brevilin A (1.25, 2.5 and 5 µM) or dexamethasone (1 µg/ml). Samples were collected after 9 and 24 h of treatment. The concentrations of IL-6 and IL-8 were quantified, and results are presented as the mean ± SEM (n=3). *P<0.05 vs. IL-17A-treated group.
Brevilin A, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-n2959/Brevilin+A/pmc12001315-26-24-33
Average 93 stars, based on 1 article reviews
brevilin a - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


Effects of brevilin A on cell viability and IL-17A induced IL-6 and IL-8 production in HaCaT cells. (A) HaCaT cells were treated with different doses of brevilin A (0.625, 1.25, 2.5, 5, 10 and 20 µM) or 2% DMSO for 24 h. Cell viability was measured by MTT assay. Results are presented as a percentage of control (untreated) cells. Data are expressed as mean ± SEM (n=3). *P<0.05 vs. control. (B) Concentrations of IL-6 and IL-8 in the supernatant were determined using ELISA kits. HaCaT cells were seeded at a density of 2×10 5 cells/well in a 24-well plate and were co-treated with IL-17A (100 ng/ml) and different concentrations of brevilin A (1.25, 2.5 and 5 µM) or dexamethasone (1 µg/ml). Samples were collected after 9 and 24 h of treatment. The concentrations of IL-6 and IL-8 were quantified, and results are presented as the mean ± SEM (n=3). *P<0.05 vs. IL-17A-treated group.

Journal: Molecular Medicine Reports

Article Title: Brevilin A inhibits IL‑17A‑induced inflammation in psoriasis by modulating HSP 70

doi: 10.3892/mmr.2025.13521

Figure Lengend Snippet: Effects of brevilin A on cell viability and IL-17A induced IL-6 and IL-8 production in HaCaT cells. (A) HaCaT cells were treated with different doses of brevilin A (0.625, 1.25, 2.5, 5, 10 and 20 µM) or 2% DMSO for 24 h. Cell viability was measured by MTT assay. Results are presented as a percentage of control (untreated) cells. Data are expressed as mean ± SEM (n=3). *P<0.05 vs. control. (B) Concentrations of IL-6 and IL-8 in the supernatant were determined using ELISA kits. HaCaT cells were seeded at a density of 2×10 5 cells/well in a 24-well plate and were co-treated with IL-17A (100 ng/ml) and different concentrations of brevilin A (1.25, 2.5 and 5 µM) or dexamethasone (1 µg/ml). Samples were collected after 9 and 24 h of treatment. The concentrations of IL-6 and IL-8 were quantified, and results are presented as the mean ± SEM (n=3). *P<0.05 vs. IL-17A-treated group.

Article Snippet: Briefly, HaCaT cells were seeded at a density of 5×10 4 cells/well in a 96-well plate, and were treated with the indicated concentrations of brevilin A (0.625–20 μM) and/or apoptozole (CAS no. 1054543-47-3; MedChemExpress) (0.009–20 μM) at 37°C for 24 h. Each concentration of each substance was tested in triplicate wells (n=3).

Techniques: MTT Assay, Control, Enzyme-linked Immunosorbent Assay

Brevilin A increases HSP 70 and HSP 90 expression in HaCaT cells. (A) HaCaT cells were treated with IL-17A alone (100 ng/ml), or were co-treated with IL-17A and brevilin A (5 µM) for different durations (0, 3, 6, 9, and 24 h). Expression levels of HSP 70, HSP 90 and β-actin (loading control) were detected by western blotting. Semi-quantitative analysis of (B) HSP 70 and (C) HSP 90 expression levels. The intensity of HSP 70/HSP 90 bands was normalized to β-actin and expressed as fold change relative to control (untreated) cells. (D) Western blot analysis of the expression levels of HSP 70 and HSP 90 in HaCaT cells treated with IL-17A (100 ng/ml) and various concentrations of brevilin A (1.25, 2.5 and 5 µM) for 9 h. β-actin was used as a loading control. (E) Semi-quantitative analysis of HSP 70 and HSP 90 band intensity was performed using ImageJ. The intensity of bands was normalized to β-actin and expressed as fold change relative to control (untreated) cells. (F) Western blot analysis of the expression levels of HSP 70 and HSP 90 in HaCaT cells treated with various concentrations of brevilin A (1.25, 2.5 and 5 µM) for 24 h. β-actin was used as a loading control. (G) Semiquantitative analysis of HSP 70 and HSP 90 band intensity was performed using ImageJ. The intensity of bands was normalized to β-actin and expressed as fold change relative to control (untreated) cells. (H) HaCaT cells were treated with IL-17A (100 ng/ml) alone, brevilin A (5 µM) alone, or a combination of IL-17A and brevilin A for 9 h. The secretion of IL-6 and IL-8 was measured by ELISA. (I) Brevilin A modulates the MAPK signaling pathway in IL-17A-treated cells. Western blot analysis was performed to assess the phosphorylation levels of SAPK/JNK, ERK and p38 MAPK after treatment with IL-17A (100 ng/ml) and different concentrations of brevilin A (1.25, 2.5 and 5 µM) for 9 h. Total SAPK/JNK, ERK and p38 protein levels were used as controls, and β-actin served as the loading control. Semi-quantification of p-SAPK/JNK, p-ERK and p-p38 was normalized to total protein levels and presented as a percentage of the control group. Data are presented as the mean ± SEM (n=3). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs. control or as indicated. HSP, heat shock protein; p-, phosphorylated.

Journal: Molecular Medicine Reports

Article Title: Brevilin A inhibits IL‑17A‑induced inflammation in psoriasis by modulating HSP 70

doi: 10.3892/mmr.2025.13521

Figure Lengend Snippet: Brevilin A increases HSP 70 and HSP 90 expression in HaCaT cells. (A) HaCaT cells were treated with IL-17A alone (100 ng/ml), or were co-treated with IL-17A and brevilin A (5 µM) for different durations (0, 3, 6, 9, and 24 h). Expression levels of HSP 70, HSP 90 and β-actin (loading control) were detected by western blotting. Semi-quantitative analysis of (B) HSP 70 and (C) HSP 90 expression levels. The intensity of HSP 70/HSP 90 bands was normalized to β-actin and expressed as fold change relative to control (untreated) cells. (D) Western blot analysis of the expression levels of HSP 70 and HSP 90 in HaCaT cells treated with IL-17A (100 ng/ml) and various concentrations of brevilin A (1.25, 2.5 and 5 µM) for 9 h. β-actin was used as a loading control. (E) Semi-quantitative analysis of HSP 70 and HSP 90 band intensity was performed using ImageJ. The intensity of bands was normalized to β-actin and expressed as fold change relative to control (untreated) cells. (F) Western blot analysis of the expression levels of HSP 70 and HSP 90 in HaCaT cells treated with various concentrations of brevilin A (1.25, 2.5 and 5 µM) for 24 h. β-actin was used as a loading control. (G) Semiquantitative analysis of HSP 70 and HSP 90 band intensity was performed using ImageJ. The intensity of bands was normalized to β-actin and expressed as fold change relative to control (untreated) cells. (H) HaCaT cells were treated with IL-17A (100 ng/ml) alone, brevilin A (5 µM) alone, or a combination of IL-17A and brevilin A for 9 h. The secretion of IL-6 and IL-8 was measured by ELISA. (I) Brevilin A modulates the MAPK signaling pathway in IL-17A-treated cells. Western blot analysis was performed to assess the phosphorylation levels of SAPK/JNK, ERK and p38 MAPK after treatment with IL-17A (100 ng/ml) and different concentrations of brevilin A (1.25, 2.5 and 5 µM) for 9 h. Total SAPK/JNK, ERK and p38 protein levels were used as controls, and β-actin served as the loading control. Semi-quantification of p-SAPK/JNK, p-ERK and p-p38 was normalized to total protein levels and presented as a percentage of the control group. Data are presented as the mean ± SEM (n=3). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs. control or as indicated. HSP, heat shock protein; p-, phosphorylated.

Article Snippet: Briefly, HaCaT cells were seeded at a density of 5×10 4 cells/well in a 96-well plate, and were treated with the indicated concentrations of brevilin A (0.625–20 μM) and/or apoptozole (CAS no. 1054543-47-3; MedChemExpress) (0.009–20 μM) at 37°C for 24 h. Each concentration of each substance was tested in triplicate wells (n=3).

Techniques: Expressing, Control, Western Blot, Enzyme-linked Immunosorbent Assay, Phospho-proteomics

Brevilin A reduces IMQ-induced skin inflammation, decreases IL-6 expression and enhances HSP 70 expression in a mouse model of psoriasis. Briefly, 8-week-old BALB/c mice (n=5/group) with IMQ-induced psoriasis were treated with brevilin A (5, 10 and 20 mg/kg) or dexamethasone (1 mg/kg) by intraperitoneal injection for 5 consecutive days. (A) Representative images of the skin on the backs of mice showed improvement in erythema and scaling in brevilin A- and dexamethasone-treated groups compared with the vehicle control. (B) Skin pathology was assessed using hematoxylin and eosin staining (×400 magnification). Representative images show the degree of epithelial hyperproliferation and immune cell infiltration, with immune cells indicated by red arrows. Scale bar=20 µm. (C) IHC staining of HSP 70 showed increased expression in brevilin A-treated groups, with the highest expression observed at 20 mg/kg. Scale bar=50 µm; ×200 magnification. (D) IHC staining of IL-6 revealed reduced expression in brevilin A-treated groups, suggesting its anti-inflammatory effects. Scale bar=50 µm; ×200 magnification. (E) IHC staining of HSP 90 showed increased expression in brevilin A-treated groups, with the highest expression observed at 20 mg/kg. Scale bar=50 µm; ×200 magnification. (F) Semi-quantification of HSP 70, IL-6 and HSP 90 staining intensity are presented as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. IHC, immunohistochemistry; IMQ, imiquimod

Journal: Molecular Medicine Reports

Article Title: Brevilin A inhibits IL‑17A‑induced inflammation in psoriasis by modulating HSP 70

doi: 10.3892/mmr.2025.13521

Figure Lengend Snippet: Brevilin A reduces IMQ-induced skin inflammation, decreases IL-6 expression and enhances HSP 70 expression in a mouse model of psoriasis. Briefly, 8-week-old BALB/c mice (n=5/group) with IMQ-induced psoriasis were treated with brevilin A (5, 10 and 20 mg/kg) or dexamethasone (1 mg/kg) by intraperitoneal injection for 5 consecutive days. (A) Representative images of the skin on the backs of mice showed improvement in erythema and scaling in brevilin A- and dexamethasone-treated groups compared with the vehicle control. (B) Skin pathology was assessed using hematoxylin and eosin staining (×400 magnification). Representative images show the degree of epithelial hyperproliferation and immune cell infiltration, with immune cells indicated by red arrows. Scale bar=20 µm. (C) IHC staining of HSP 70 showed increased expression in brevilin A-treated groups, with the highest expression observed at 20 mg/kg. Scale bar=50 µm; ×200 magnification. (D) IHC staining of IL-6 revealed reduced expression in brevilin A-treated groups, suggesting its anti-inflammatory effects. Scale bar=50 µm; ×200 magnification. (E) IHC staining of HSP 90 showed increased expression in brevilin A-treated groups, with the highest expression observed at 20 mg/kg. Scale bar=50 µm; ×200 magnification. (F) Semi-quantification of HSP 70, IL-6 and HSP 90 staining intensity are presented as the mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. IHC, immunohistochemistry; IMQ, imiquimod

Article Snippet: Briefly, HaCaT cells were seeded at a density of 5×10 4 cells/well in a 96-well plate, and were treated with the indicated concentrations of brevilin A (0.625–20 μM) and/or apoptozole (CAS no. 1054543-47-3; MedChemExpress) (0.009–20 μM) at 37°C for 24 h. Each concentration of each substance was tested in triplicate wells (n=3).

Techniques: Expressing, Injection, Control, Staining, Immunohistochemistry

Apoptozole neutralizes the effects of brevilin A on decreasing IL-17A-induced IL-6 and IL-8 levels. HaCaT cells were seeded at a density of 2×10 5 cells/well in a 24-well plate, and were co-treated with IL-17A (100 ng/ml), either brevilin A (5 µM) and different concentrations of apoptozole (1.25, 2.5 and 5 µM) for 9 and 24 h. Levels of IL-6 and IL-8 were measured by ELISA. Data are presented as the mean ± SEM (n=3). *P<0.05 vs. IL-17A-treated group; # P<0.05 vs. IL-17A + brevilin A co-treated group.

Journal: Molecular Medicine Reports

Article Title: Brevilin A inhibits IL‑17A‑induced inflammation in psoriasis by modulating HSP 70

doi: 10.3892/mmr.2025.13521

Figure Lengend Snippet: Apoptozole neutralizes the effects of brevilin A on decreasing IL-17A-induced IL-6 and IL-8 levels. HaCaT cells were seeded at a density of 2×10 5 cells/well in a 24-well plate, and were co-treated with IL-17A (100 ng/ml), either brevilin A (5 µM) and different concentrations of apoptozole (1.25, 2.5 and 5 µM) for 9 and 24 h. Levels of IL-6 and IL-8 were measured by ELISA. Data are presented as the mean ± SEM (n=3). *P<0.05 vs. IL-17A-treated group; # P<0.05 vs. IL-17A + brevilin A co-treated group.

Article Snippet: Briefly, HaCaT cells were seeded at a density of 5×10 4 cells/well in a 96-well plate, and were treated with the indicated concentrations of brevilin A (0.625–20 μM) and/or apoptozole (CAS no. 1054543-47-3; MedChemExpress) (0.009–20 μM) at 37°C for 24 h. Each concentration of each substance was tested in triplicate wells (n=3).

Techniques: Enzyme-linked Immunosorbent Assay

Effects of brevilin A treatment on anti-inflammatory cytokines were reversed by apoptozole treatment. HaCaT cells were seeded at a density of 2×10 5 cells/well in a 24-well plate, and were co-treated with IL-17A (100 ng/ml), brevilin A (1.25, 2.5 and 5 µM) and apoptozole (5 µM). Samples were collected after 9 and 24 h of treatment. Levels of IL-6 and IL-8 were measured by ELISA. Data are presented as the mean ± SEM (n=3). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Journal: Molecular Medicine Reports

Article Title: Brevilin A inhibits IL‑17A‑induced inflammation in psoriasis by modulating HSP 70

doi: 10.3892/mmr.2025.13521

Figure Lengend Snippet: Effects of brevilin A treatment on anti-inflammatory cytokines were reversed by apoptozole treatment. HaCaT cells were seeded at a density of 2×10 5 cells/well in a 24-well plate, and were co-treated with IL-17A (100 ng/ml), brevilin A (1.25, 2.5 and 5 µM) and apoptozole (5 µM). Samples were collected after 9 and 24 h of treatment. Levels of IL-6 and IL-8 were measured by ELISA. Data are presented as the mean ± SEM (n=3). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Article Snippet: Briefly, HaCaT cells were seeded at a density of 5×10 4 cells/well in a 96-well plate, and were treated with the indicated concentrations of brevilin A (0.625–20 μM) and/or apoptozole (CAS no. 1054543-47-3; MedChemExpress) (0.009–20 μM) at 37°C for 24 h. Each concentration of each substance was tested in triplicate wells (n=3).

Techniques: Enzyme-linked Immunosorbent Assay